COVID-19: How Orbis International is managing operations

Article

Danny Haddad, MD, chief of program at Orbis International, shares an update on how the company's operations have shifted during the coronavirus pandemic, as well as the record-breaking impact on one of its telehealth platforms.
 


See more coronavirus coverage here

 

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
A phone with the US Food and Drug Administration (FDA) logo on the screen. Image credit: ©gguy – stock.adobe.com

US FDA approves revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2

Martin David Harp;Hattie Hayes
March 6th 2025
Article

The encapsulated cell therapy from Neurotech Pharmaceuticals is the first FDA-approved treatment for MacTel

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Site Logo

Enhancing the Patient Journey Solutions to Overcoming Challenges in Glaucoma Management

March 5th 2025
Article
PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Site Logo

Enhancing the Patient Journey Solutions for Confident Refractive Planning and Follow-up

March 5th 2025
Article
Site Logo

Enhancing the Patient Journey Solutions for Effective GA Management

March 5th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.